Pfizer

₹4850 41.6 | 0.9%

WEBSITE BSE:500680 NSE : PFIZER LTD. 26 Dec, 16:01

Market Cap ₹22188 Cr.

Stock P/E 40.2

P/B 5.9

Current Price ₹4850

Book Value ₹ 819.9

Face Value 10

52W High ₹6452.9

Dividend Yield 0.72%

52W Low ₹ 4050.1

Edit Ratio

Pfizer Research see more...

Overview Inc. Year: 1950Industry: Pharmaceuticals & Drugs

Pfizer Ltd is an India-based pharmaceutical agency. The Company has a portfolio of approximately 150 products across over 15 therapeutic areas. The Company is engaged in production, advertising, buying and selling and exporting pharmaceutical products. The Company gives various merchandise for anti-diabetic, erectile disorder, gastrointestinal (GI), multivitamins, anti-infectives, cardiovascular, dermatology, neurology, ache/fever/infection and autoimmune problems, amongst others. Its merchandise consist of Viagra, Daxid, Tricorex, Mucaine, Diamox, Hetrazan, Enbrel, Ativan, Pacitane, Folvite Tablets, Autrin Capsules, Prevenar 13, Wysolone, Loette, anti-infectives, cardiovascular, dermatology, Trulimax, Vibazime DT, Ovral G, Ovral L, Premarin pills, Premarin Vaginal Cream, Zosyn, Wymox, Tygacil, Cynomycin, Targit, Cyklokapron and Magnamycin. The Company has its personal production facility at Thane and Goa. The Company has numerous impartial settlement/third party manufacturers based throughout the country.

Pfizer Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Pfizer Quarterly Results

#(Fig in Cr.)	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Net Sales	593	637	622	573	531	575	540	547	563	589
Other Income	18	24	27	31	33	36	36	75	42	43
Total Income	611	662	649	604	565	611	576	622	605	632
Total Expenditure	401	406	418	391	421	393	387	357	385	399
Operating Profit	210	256	231	213	144	219	188	265	219	232
Interest	4	3	4	3	3	3	3	7	2	2
Depreciation	27	26	26	26	16	15	18	14	15	15
Exceptional Income / Expenses	-136	189	0	-20	0	0	8	0	0	0
Profit Before Tax	43	415	201	165	126	201	176	244	203	215
Provision for Tax	11	104	50	35	32	52	46	65	52	57
Profit After Tax	33	311	151	130	94	149	130	179	151	158
Adjustments	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	33	311	151	130	94	149	130	179	151	158
Adjusted Earnings Per Share	7.1	68	32.9	28.3	20.4	32.6	28.4	39.1	32.9	34.6

Pfizer Profit & Loss

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Net Sales	1112	1853	2012	1966	1969	2082	2152	2239	2611	2425	2193	2239
Other Income	109	72	87	101	114	167	184	81	63	101	181	196
Total Income	1221	1925	2099	2067	2083	2249	2336	2320	2674	2526	2374	2435
Total Expenditure	873	1474	1579	1616	1468	1516	1579	1526	1775	1616	1558	1528
Operating Profit	349	451	520	451	615	733	757	794	899	910	816	904
Interest	1	2	1	2	1	2	11	15	11	13	15	14
Depreciation	8	131	58	63	66	71	103	109	115	106	62	62
Exceptional Income / Expenses	0	-80	10	130	0	0	0	0	0	33	8	8
Profit Before Tax	340	238	470	517	548	660	642	669	773	824	746	838
Provision for Tax	119	138	165	180	188	231	133	171	160	200	195	220
Profit After Tax	221	100	305	337	360	429	509	498	613	624	551	618
Adjustments	0	-31	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	221	70	305	337	360	429	509	498	613	624	551	618
Adjusted Earnings Per Share	74	21.9	66.7	73.6	78.7	93.8	111.3	108.8	133.9	136.4	120.5	135

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	-10%	-1%	1%	7%
Operating Profit CAGR	-10%	1%	2%	9%
PAT CAGR	-12%	3%	5%	10%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	15%	-1%	3%	9%
ROE Average	16%	20%	19%	16%
ROCE Average	22%	27%	25%	24%

Pfizer Balance Sheet

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Shareholder's Funds	658	1973	2163	2419	2683	3011	3395	2393	2864	3207	3596
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	0	3	3	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	-19	-37	64	62	52	37	136	85	136	38	33
Total Current Liabilities	303	609	658	780	954	892	873	774	853	657	547
Total Liabilities	942	2547	2888	3261	3690	3940	4405	3252	3854	3903	4175
Fixed Assets	20	944	925	867	917	854	942	865	841	749	713
Other Non-Current Assets	237	350	331	343	357	371	415	479	616	629	693
Total Current Assets	686	1252	1614	2033	2403	2702	3013	1873	2361	2493	2738
Total Assets	942	2547	2888	3261	3690	3940	4405	3252	3854	3903	4175

Pfizer Cash Flow

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Opening Cash & Cash Equivalents	1433	308	488	71	68	51	74	1764	151	63	37
Cash Flow from Operating Activities	132	113	345	329	332	98	323	427	667	356	257
Cash Flow from Investing Activities	103	-89	-701	-250	-238	35	1530	-469	-575	-36	54
Cash Flow from Financing Activities	-1360	-1	-62	-83	-110	-110	-164	-1571	-181	-346	-235
Net Cash Inflow / Outflow	-1125	23	-417	-3	-17	23	1690	-1613	-88	-26	75
Closing Cash & Cash Equivalent	308	488	71	68	51	74	1764	151	63	37	112

Pfizer Ratios

#	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Earnings Per Share (Rs)	74.01	21.93	66.67	73.61	78.7	93.78	111.29	108.77	133.89	136.38	120.51
CEPS(Rs)	76.68	50.59	79.33	87.37	93.18	109.39	133.85	132.68	159.03	159.44	134.12
DPS(Rs)	360	12.5	15	20	20	22.5	330	35	30	70	35
Book NAV/Share(Rs)	220.64	431.28	472.92	528.72	586.49	658.22	742.18	523.07	626.1	701.05	785.91
Core EBITDA Margin(%)	20.54	19.69	20.67	17.15	25.28	27.17	26.62	31.82	30.79	31.6	27.43
EBIT Margin(%)	29.24	12.43	22.53	25.41	27.71	31.79	30.37	30.56	28.86	32.71	32.88
Pre Tax Margin(%)	29.15	12.36	22.47	25.31	27.67	31.7	29.86	29.87	28.46	32.18	32.21
PAT Margin (%)	18.96	5.21	14.57	16.49	18.18	20.61	23.66	22.23	22.56	24.37	23.81
Cash Profit Margin (%)	19.64	12.01	17.33	19.58	21.53	24.04	28.46	27.12	26.79	28.49	26.49
ROA(%)	14.91	5.75	11.22	10.95	10.36	11.25	12.2	13	17.24	16.09	13.65
ROE(%)	18.77	7.63	14.75	14.7	14.11	15.07	15.89	17.19	23.3	20.55	16.21
ROCE(%)	28.96	18.19	22.78	22.62	21.49	23.22	20.38	23.62	29.78	27.56	22.37
Receivable days	49.42	31.59	26.35	22.58	24.43	28.62	29.15	22.89	16.89	20.98	26.74
Inventory Days	49.61	51.1	65.25	61.01	57.05	59.95	69.32	70.57	59.41	61.77	67.09
Payable days	185.5	138.79	175.52	186.15	238.01	250.57	212.28	176.59	114.15	109.36	95.85
PER(x)	17.08	101.69	26.8	25.71	27.77	35.41	36.17	41.57	32.5	25.4	34.8
Price/Book(x)	5.73	5.17	3.78	3.58	3.73	5.04	5.42	8.64	6.95	4.94	5.34
Dividend Yield(%)	28.48	0.56	0.84	1.06	0.92	0.68	8.2	0.77	0.69	2.02	0.83
EV/Net Sales(x)	3.12	5.18	3.55	3.63	4.18	6.38	7.53	8.74	7	5.77	7.82
EV/Core EBITDA(x)	9.94	21.28	13.76	15.82	13.38	18.12	21.4	24.67	20.33	15.37	21.01
Net Sales Growth(%)	6	66.69	8.58	-2.29	0.11	5.74	3.37	4.04	16.64	-7.13	-9.55
EBIT Growth(%)	-51.02	-29.69	96.98	9.96	5.76	20.59	-1.23	4.68	14.54	6.88	-9.07
PAT Growth(%)	-56.11	-54.57	203.95	10.43	6.92	19.16	18.66	-2.26	23.1	1.86	-11.64
EPS Growth(%)	-56.11	-70.36	203.95	10.42	6.92	19.16	18.66	-2.26	23.1	1.86	-11.64
Debt/Equity(x)	0	0	0	0	0	0	0	0	0	0	0
Current Ratio(x)	2.26	2.06	2.45	2.61	2.52	3.03	3.45	2.42	2.77	3.79	5.01
Quick Ratio(x)	1.76	1.42	1.9	2.19	2.21	2.6	2.96	1.87	2.24	3.16	4.22
Interest Cover(x)	310.56	158.68	337.93	264.69	712.57	384.67	59.36	44.45	73.23	62.13	49.35
Total Debt/Mcap(x)	0	0	0	0	0	0	0	0	0	0	0

Pfizer Shareholding Pattern

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	63.92	63.92	63.92	63.92	63.92	63.92	63.92	63.92	63.92	63.92
FII	2.55	2.55	2.77	2.8	2.81	2.82	3.03	3.32	3.22	3.54
DII	14.83	14.88	14.93	14.9	14.89	15.01	15.15	15.33	15.84	16.03
Public	18.7	18.65	18.38	18.38	18.38	18.25	17.9	17.42	17.02	16.5
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	2.92	2.92	2.92	2.92	2.92	2.92	2.92	2.92	2.92	2.92
FII	0.12	0.12	0.13	0.13	0.13	0.13	0.14	0.15	0.15	0.16
DII	0.68	0.68	0.68	0.68	0.68	0.69	0.69	0.7	0.72	0.73
Public	0.86	0.85	0.84	0.84	0.84	0.83	0.82	0.8	0.78	0.76
Others	0	0	0	0	0	0	0	0	0	0
Total	4.57	4.57	4.57	4.57	4.57	4.57	4.57	4.57	4.57	4.57

Pros

Debtor days have improved from 109.36 to 95.85days.
Company is almost debt free.

Cons

Stock is trading at 5.9 times its book value.
The company has delivered a poor profit growth of 5% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Pfizer News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Pfizer

Add Watchlist

Pfizer Research see more...

Overview Inc. Year: 1950Industry: Pharmaceuticals & Drugs

Pfizer Share Price

Alert Data

Quarterly Price

Peer Comparison

Pfizer Quarterly Results

Pfizer Profit & Loss

Growth Rates

Pfizer Balance Sheet

Pfizer Cash Flow

Pfizer Ratios

Pfizer Shareholding Pattern

Pfizer News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!